• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHOU Ping, LI Li, WU Lulu, GU Chenhao, TIAN Huimin, REN Xiaoming, ZHANG Haijun, WU Jiaquan. Determination of osimertinib mesylate by HPLC[J]. Journal of China Pharmaceutical University, 2017, 48(3): 322-327. DOI: 10.11665/j.issn.1000-5048.20170312
Citation: ZHOU Ping, LI Li, WU Lulu, GU Chenhao, TIAN Huimin, REN Xiaoming, ZHANG Haijun, WU Jiaquan. Determination of osimertinib mesylate by HPLC[J]. Journal of China Pharmaceutical University, 2017, 48(3): 322-327. DOI: 10.11665/j.issn.1000-5048.20170312

Determination of osimertinib mesylate by HPLC

More Information
  • To establish an HPLC method to determine osimertinib mesylate, Agilent ZORBAX Eclipse Plus C18 column(4. 6 mm × 250 mm, 5 μm)was used with a mobile phase consisting of methanol-buffer solution(20 mmol/L NaH2PO4, pH 3. 0 adjusted with 85% H3PO4)(50 ∶50)at the flow rate of 1. 0 mL/min. The detection wavelength was 210 nm, and the column temperature was kept at 35 ℃. The calibration curve was liner over the range from 50% to 150% of determination concentration(0. 201 1- 0. 603 2 mg/mL, r=0. 999 9). The limit of quantitation(LOQ)and limit of detection(LOD)were 0. 32 μg/mL and 0. 08 μg/mL, respectively. The contents of osimertinib mesylate in samples were 100. 1%, 99. 5% and 99. 7%. Good chromatographic separation of osimertinib mesylate and its related substances, including synthetic impurities and degradation products, were obtained. The established HPLC method is specific, accurate, simple and durable, and could be used for the determination of osimertinib mesylate.
  • [1]
    Cross DA,Ashton SE,Ghiorghiu S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer Discov,2014,4(9):1046-1061.
    [2]
    Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
    [3]
    Yang X,Liangan C.Advances in primary resistance to EGFR-TKI in patients with non-small cell lung cancer[J].Acad J Chin PLA Med Sch(解放军医学院学报),2013,34(4):418-420.
    [4]
    Jiang T,Zhou C.Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer[J].Trans Lung Cancer Res,2014,3(6):370-372.
    [5]
    U.S.Food and Drug Administration.FDA approves new pill to treat certain patients with non-small cell lung cancer[EB/OL].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
    [6]
    Liu H,Lyu Y,Li Y,et al.A novel and efficient synthesis of anti-cancer agent,mereletinib[J].J Chem Res,2015,39(6):318-320.
    [7]
    Butterworth S,Finlay MR,Ward RA,et al.Preparation of 2-(2,4,5-substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer:WO,2013/14448[P].2012-07-25[2013-01-31] .
    [8]
    Rood JJ,van Bussel MT,Schellens JH,et al.Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib(AZD9291)in human plasma[J].J Chromatogr B,2016,1031:80-85.
  • Related Articles

    [1]JI Shunli, SONG Fanfan, ZHENG Yang, DING Li. Simultaneous determination of amoxicillin and clavulanic acid by LC-MS/MS in human plasma and its application to a bioequivalence study[J]. Journal of China Pharmaceutical University, 2019, 50(6): 699-706. DOI: 10.11665/j.issn.1000-5048.20190610
    [2]LI Jingjing, TAN Jingfu, YANG Jie, WANG Qiang. Pharmacokinetic study of corosolic acid in normal rats and diabetic rats by LC-MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 84-87. DOI: 10.11665/j.issn.1000-5048.20140115
    [3]MU Yanan, YANG Jin. Determination of epothilone B in human blood by LC-MS/MS and its application in phase I pharmacokinetics study[J]. Journal of China Pharmaceutical University, 2013, 44(1): 89-92. DOI: 10.11665/j.issn.1000-5048.20130115
    [4]SI Qian, CHEN Yuan-cheng, HUANG Li-hua, CHENG Yu, HE Hua, LIU Xiao-quan. Determination of nebivolol in human plasma by LC-MS/MS and study of its pharmacokinetics on the Chinese[J]. Journal of China Pharmaceutical University, 2011, 42(2): 136-140.
    [5]WU Fei, GAO Fang, DING Li, MAO Xiao-ming, MA Peng-cheng. Determination of zofenopril and its active metabolite zofenoprilat by a new derivative LC-MS method and their pharmacokinetics in healthy Chinese volunteers[J]. Journal of China Pharmaceutical University, 2009, 40(4): 353-358.
    [6]Determination of Ranolazine and Its Pharmacokinetics in Dog by LC-MS[J]. Journal of China Pharmaceutical University, 2004, (2): 59-62.
    [7]Determination of Clarithromycin in Human Plasma by LC-MS Method[J]. Journal of China Pharmaceutical University, 2004, (1): 52-55.
    [8]Study of Pharmacokinetics and Relative Bioavailability of Clarithromycin[J]. Journal of China Pharmaceutical University, 2003, (4): 23-26.
    [9]Determination of Descarboethoxyloratadine and Its Pharmaco-kinetics in Human Plasma by LC-MS[J]. Journal of China Pharmaceutical University, 2002, (4): 46-49.
    [10]Pharmacokinetics and Relative Bioavailability of Cyclosporin Pearls in Healthy Volunteers[J]. Journal of China Pharmaceutical University, 1996, (6): 20-22.
  • Cited by

    Periodical cited type(4)

    1. 刘海帆,崔洁,王文全. 甘草地上部分黄酮类成分的代谢物及药代动力学参数研究概述. 天津中医药大学学报. 2022(01): 90-101 .
    2. 卞莹莹,邹纯才,鄢海燕,孙德考,胡倩. LC-MS/MS法研究瓜蒌缓释微丸在大鼠体内的药代动力学特征. 南方医科大学学报. 2020(07): 995-1000 .
    3. 潘诗苑,邹巧根,韩茉,高倩倩. UPLC-MS/MS测定人血浆中咪达那新的浓度及其生物等效性研究. 中国药科大学学报. 2019(05): 579-584 . 本站查看
    4. 刘博文,刘富垒,王如意,薛经纬,柳文媛,冯锋,曲玮. 苦木总生物碱的化学成分分析及其对大鼠胶原诱导性关节炎的作用. 中国药科大学学报. 2019(05): 585-592 . 本站查看

    Other cited types(3)

Catalog

    Article views (2432) PDF downloads (3485) Cited by(7)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return